Skip to main content

Table 1 Patient’s characteristics

From: Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities

CRI number Age at liver procedure Sex Primary tumor T stage Primary tumor N stage Primary tumor M stage Post primary resection chemotx Adjuvant chemo before liver resection Time between resection and chemotx (Days)
CRI 1010 60 F 3 0 0 None Bevacizumab, Oxaliplatin, Capecitabine 49
CRI 1012 53 M 3 0 0 5FU + Leukovorin FOLFOX + avastin 209
CRI 1091 60 M 3 2 1 FOLFOX FOLFOX 52
CRI 1101 47 F 3 1 1 FOLFOX + avastin FOLFOX + avastin 36
CRI 1109 70 M 4 1 1 XELOX XELOX 52
CRI 1102 55 M 3 2 1 FOLFOX + avastin FOLFOX + avastin 133
CRI 1126 60 F 3 1 1 FOLFOX FOLFOX + avastin 487
CRI 1129 79 M     None Capecitabine 53
CRI 1109 70 M 4 1 1 XELOX XELOX 123
CRI 1208 83 F 3 1 0 XELOX FOLFIRI + avastin 103
CRI 1109 70 M 4 1 1 n/a n/a n/a
CRI 1197 73 F    1 FOLFOX FOLFOX 89
CRI 1400 77 M 3 0 1 Modified FOLFOX None 185
CRI 1405 33 F 3 0 1 FOLFOX FOLFOX 36
CRI 1404 50 F 3 0 0 None FOLFOX 35
CRI 1513 29 F 4a 2b 0 FOLFOX None None